Abiopharma

Cadrenal Therapeutics Inc (CVKD) Announces Clinical Trial Update Cadrenal Therapeutics Inc (CVKD) provided an update on its clinical development programs. Clinical Development Highlights:

• Drug Program: opportunity
• Diseases/Conditions: clinical testing
• Clinical Stage: Phase 2
• Collaboration: cadrenal.htm PRESS RELEASE OF CADRENAL THERAPEUTICS, INC
• Updated Timeline: December 11, 2025, DECEMBER 11, 2025
  • targeting 12-LOX are also under development for type 1 diabetes and other immune-mediated and inflammatory diseases. “We are pleased the advancement of VLX-1005
  • targeting a critical immune signaling pathway. This acquisition addresses yet another underserved therapeutic opportunity in the $40 billion global anticoagulation market. VLX-1005
  • targeting a key immune signaling pathway and the underlying cause of HIT ●It is the first and only potent, highly selective inhibitor of human 12-LOX in clinical testing, distinguishing it from related compounds. ●Orphan Drug and Fast Track designations from the FDA PONTE VEDRA, FL, December 11, 2025